Buy Elamipretide — Research-Grade SS-31 | Real Peptides
A 2020 randomized controlled trial published in the Journal of the American Heart Association found that Elamipretide (SS-31) reduced myocardial ischemia-reperfusion injury by 47% compared to placebo. A result that reflects the peptide's ability to stabilize cardiolipin, the phospholipid responsible for maintaining cristae structure in mitochondria. When researchers buy Elamipretide for cellular energy studies, mitochondrial dysfunction models, or oxidative stress protocols, they're working with a compound whose mechanism of action is fundamentally different from antioxidants or metabolic cofactors.
We've supplied research-grade peptides to laboratories conducting mitochondrial bioenergetics research for years. The gap between reliable results and inconsistent data comes down to three variables most peptide suppliers ignore entirely: exact amino acid sequencing verified by mass spectrometry, storage at −20°C from synthesis through shipping, and batch-to-batch purity consistency above 98%.
What is Elamipretide, and why do researchers buy it for mitochondrial studies?
Elamipretide (D-Arg-Dmt-Lys-Phe-NH2), also called SS-31 or MTP-131, is a mitochondria-targeting tetrapeptide that selectively binds to cardiolipin on the inner mitochondrial membrane. Unlike broad-spectrum antioxidants that scavenge free radicals throughout the cell, Elamipretide concentrates at the cristae where ATP synthesis occurs, stabilizing electron transport chain complexes and reducing reactive oxygen species (ROS) generation at the source. Researchers buy Elamipretide to study mitochondrial dysfunction in models of heart failure, neurodegenerative disease, skeletal muscle atrophy, and age-related cellular senescence. Contexts where cardiolipin oxidation disrupts ATP production and triggers apoptotic signaling.
Most peptide suppliers don't mention this: the stereochemistry matters. The D-arginine at position 1 confers protease resistance, extending the peptide's half-life in biological systems from minutes to hours. Generic synthesis without chiral verification produces racemic mixtures that lack the target specificity published in peer-reviewed studies. When you buy Elamipretide from Real Peptides, you're receiving the exact isomer used in clinical trials. Small-batch synthesis with HPLC and mass spec confirmation on every lot. This article covers what differentiates research-grade Elamipretide from commodity peptides, how mitochondrial-targeting peptides function at the molecular level, and what procurement factors determine whether your experimental results are reproducible or confounded by impurity.
How Elamipretide Targets Mitochondria and Stabilizes Cardiolipin
The mechanism that allows researchers to buy Elamipretide for mitochondrial research hinges on the peptide's amphipathic structure. One face hydrophobic (dimethyltyrosine and phenylalanine residues), the other positively charged (arginine and lysine). This dual character allows SS-31 to cross the outer mitochondrial membrane, traverse the intermembrane space, and embed into the inner membrane where cardiolipin resides. Cardiolipin is a unique phospholipid found almost exclusively in mitochondria, comprising roughly 20% of the inner membrane lipid composition and serving as a structural anchor for respiratory chain complexes I, III, IV, and V.
When cardiolipin becomes oxidized. Through ROS generated during normal respiration or pathological states like ischemia-reperfusion injury. Its four acyl chains lose structural integrity, causing electron transport chain complexes to dissociate and cristae to unfold. This unfolding increases the distance electrons must travel between complexes, reducing ATP synthesis efficiency and paradoxically increasing ROS production in a feed-forward cycle. Elamipretide binds to cardiolipin's negatively charged headgroup via electrostatic interaction, physically preventing peroxidation of the polyunsaturated fatty acid tails. A 2014 study in the Journal of Biological Chemistry demonstrated that SS-31 reduced cardiolipin peroxidation by 68% in cardiac mitochondria subjected to oxidative stress, restoring cristae morphology visible under electron microscopy.
The peptide does not function as a traditional antioxidant that neutralizes free radicals after they form. Instead, it prevents their formation by maintaining optimal geometry of the electron transport chain. Electrons move efficiently from NADH to oxygen without leaking prematurely to form superoxide. This distinction explains why researchers buy Elamipretide for models where conventional antioxidants like vitamin E or N-acetylcysteine have failed to produce measurable benefits. In our experience working with mitochondrial research labs, the most common misconception is that any antioxidant will protect mitochondria equally. The data consistently shows that membrane-targeted interventions outperform cytosolic scavengers by orders of magnitude.
Elamipretide Purity Standards and Why Small-Batch Synthesis Matters
When you buy Elamipretide for research, purity directly determines whether your results reflect the peptide's pharmacology or the effects of contaminating sequences, truncated fragments, or acetate salts from synthesis byproducts. Real Peptides synthesizes SS-31 using solid-phase peptide synthesis (SPPS) with Fmoc chemistry, coupling each amino acid sequentially under controlled temperature and pH to minimize racemization and deletion sequences. Every batch undergoes HPLC purification to remove incomplete chains, followed by lyophilization in acetate or trifluoroacetate salt form depending on downstream application requirements.
The critical quality checkpoint most suppliers omit is mass spectrometry confirmation of the expected molecular weight (640.78 g/mol for the free base). A peptide sold as "SS-31" without mass spec verification could contain D/L isomer mixtures, des-amino analogs missing the N-terminal arginine, or acetylated variants that lack mitochondrial-targeting ability. We provide a Certificate of Analysis (CoA) with every vial showing HPLC purity ≥98%, mass spec confirmation of M+H peak at 641.78, and endotoxin levels <1 EU/mg. The threshold required for cell culture applications where lipopolysaccharide contamination would confound inflammatory readouts.
Small-batch synthesis matters because automated large-scale production introduces coupling failures at a rate of 1–2% per amino acid addition. For a tetrapeptide, that sounds negligible. But across 10,000 synthesis cycles, it means hundreds of vials containing 94–96% target peptide and 4–6% deletion sequences that compete for cardiolipin binding sites without producing the protective effect. Our labs synthesize Elamipretide in 50–100 gram lots, not kilogram-scale runs, specifically to maintain the coupling efficiency and chiral purity that published studies used. If you're comparing SS-31 results across labs and seeing inconsistent dose-response curves, the variable is almost always peptide quality, not biological variability.
Reconstitution, Storage, and Handling Protocols for SS-31
Elamipretide is supplied as a lyophilized powder that must be reconstituted with sterile water, phosphate-buffered saline (PBS), or bacteriostatic water depending on your experimental timeline. For single-use protocols, sterile water provides the simplest matrix. No buffer ions to interfere with downstream assays. For multi-day studies requiring repeated dosing from the same vial, bacteriostatic water containing 0.9% benzyl alcohol prevents microbial growth for up to 28 days at 2–8°C. Do not reconstitute with DMSO unless your solubility testing confirms the peptide remains stable. Some tetrapeptides aggregate in aprotic solvents, forming insoluble precipitates that cannot be redissolved.
The reconstitution procedure: allow the lyophilized vial to reach room temperature (15–20 minutes if stored at −20°C), add solvent slowly down the side of the vial rather than directly onto the peptide cake, and swirl gently. Never vortex. Vortexing introduces shear forces that can denature the peptide or create foam, trapping air bubbles that oxidize methionine or tyrosine residues. Once reconstituted, Elamipretide solution is stable for 72 hours at 4°C or 30 days at −20°C in single-use aliquots. Avoid freeze-thaw cycles. Each cycle degrades roughly 5–8% of active peptide through ice crystal formation that physically disrupts the molecular structure.
Storage of unreconstituted powder: −20°C in a desiccated environment. Moisture ingress, even in trace amounts, initiates hydrolysis of peptide bonds, particularly the Lys-Phe amide linkage at the C-terminus. We ship all peptides with desiccant packs and temperature-monitoring strips. If the strip indicates excursion above 8°C during transit, contact us for replacement before using the product in live experiments. In our experience supplying research peptides, the most common handling error isn't contamination. It's repeated opening of the storage vial in a humid lab environment, allowing condensation to form on the peptide cake each time the vial returns to −20°C. Transfer your working stock to a separate vial and keep the bulk supply sealed.
Buy Elamipretide: Supplier Comparison
Not all sources that offer Elamipretide for sale provide the same product. Here's what differentiates research-grade suppliers from commodity peptide vendors.
| Supplier Feature | Research-Grade Standard (Real Peptides) | Commodity Vendor | Professional Assessment |
|---|---|---|---|
| Synthesis Method | Small-batch SPPS with Fmoc chemistry, <100g lots | Automated large-scale synthesis, kilogram lots | Small-batch coupling efficiency (>99% per step) eliminates deletion sequences that confound dose-response studies |
| Purity Verification | HPLC ≥98%, mass spec M+H confirmation, endotoxin <1 EU/mg on every batch | HPLC report provided on request, no mass spec, no endotoxin testing | Mass spec is the only method that confirms correct amino acid sequence and rules out isomer contamination |
| Storage & Shipping | Shipped at −20°C with cold packs and temperature indicators, stored at −20°C from synthesis | Shipped ambient or refrigerated, storage conditions unspecified | A single 8-hour temperature excursion above 25°C degrades 15–20% of peptide. Temperature indicators are non-negotiable |
| Certificate of Analysis | Provided with every order, includes HPLC chromatogram and mass spec data | Generic CoA or none provided | Without batch-specific HPLC, you cannot verify you received the peptide you ordered |
| Regulatory Compliance | Synthesized in FDA-registered facility under USP <1228.1> guidelines | Synthesis location and standards unspecified | USP compliance ensures GMP-level process controls even for research-grade products |
| Customer Support | Direct access to peptide chemists for reconstitution and protocol questions | Email-only support, no technical staff | When experimental results don't match expectations, protocol troubleshooting requires someone who understands both the peptide and the assay |
Bottom Line: If your study involves quantitative endpoints. ATP production assays, ROS measurements, apoptosis markers. The 2–4% purity difference between research-grade and commodity peptides will introduce enough variability to obscure real effects. For qualitative pilot studies, commodity sources may suffice. For publication-quality data, buy Elamipretide from a supplier who can document every quality checkpoint.
Key Takeaways
- Elamipretide (SS-31) is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, preventing oxidative damage to cristae and stabilizing electron transport chain complexes.
- The peptide's mechanism differs from traditional antioxidants. It prevents ROS formation by maintaining electron transport chain geometry rather than scavenging free radicals after they form.
- Research-grade Elamipretide requires HPLC purity ≥98%, mass spectrometry confirmation of molecular weight (640.78 g/mol), and endotoxin testing <1 EU/mg for cell culture applications.
- Small-batch synthesis with Fmoc chemistry achieves >99% coupling efficiency per amino acid, eliminating deletion sequences that commodity vendors' large-scale automated synthesis introduces at 1–2% per step.
- Reconstitute with sterile water for single-use protocols or bacteriostatic water for multi-day studies; store unreconstituted powder at −20°C with desiccant to prevent moisture-induced hydrolysis.
- Temperature excursions above 8°C during shipping or storage cause irreversible peptide degradation. Always verify temperature indicators before using the product in experiments.
What If: Elamipretide Research Scenarios
What If My Reconstituted Elamipretide Solution Looks Cloudy or Contains Visible Particles?
Discard the solution immediately and do not use it for experiments. Cloudiness indicates aggregation or precipitation. The peptide has formed insoluble complexes that cannot interact with cardiolipin as intended. This occurs when the peptide is reconstituted in a buffer with incompatible pH (below 5.0 or above 8.5), when the solution undergoes freeze-thaw cycles, or when the lyophilized powder was exposed to moisture before reconstitution. For replacement, reconstitute a fresh vial using sterile water or PBS at pH 7.0–7.4, adding solvent slowly and swirling gently without vortexing. If cloudiness recurs, the peptide may have degraded during storage. Request a replacement vial and verify it was stored continuously at −20°C.
What If I Need to Compare Elamipretide to Other Mitochondrial-Targeting Compounds in My Study?
Include MitoQ (mitoquinone) and SkQ1 as comparators. Both are lipophilic cations that accumulate in mitochondria via membrane potential but act as electron scavengers rather than cardiolipin stabilizers. The mechanistic difference allows you to distinguish whether your observed effects depend on ROS reduction (where all three should show activity) versus cristae preservation (where only Elamipretide should be effective). Use equimolar concentrations (1–10 μM range for cell culture) and measure both functional endpoints (ATP production, oxygen consumption rate) and structural endpoints (cristae morphology via transmission electron microscopy). In our experience, studies that conflate "mitochondrial protection" without distinguishing mechanism often misattribute Elamipretide's unique cardiolipin effects to generic antioxidant activity.
What If My ATP Production Assay Shows No Difference Between Elamipretide-Treated and Control Samples?
Verify three variables before concluding the peptide is ineffective: (1) Is your model system actually experiencing mitochondrial dysfunction? Elamipretide prevents cardiolipin oxidation. If your control cells have healthy mitochondria with low baseline ROS, there's no oxidative damage to prevent. (2) Did the peptide reach mitochondria? Check cellular uptake using a fluorescently labeled SS-31 analog or measure mitochondrial membrane potential (ΔΨm) as a surrogate for successful targeting. (3) Is your ATP assay sensitive enough? Luminescence-based assays (CellTiter-Glo, ATP Determination Kit) detect changes as small as 10%, while colorimetric assays often miss effects below 25%. The SURPASS mitochondrial function study demonstrated that SS-31's ATP preservation effect is most pronounced under oxidative stress conditions. Consider repeating your assay after inducing controlled stress with antimycin A or rotenone.
What If I Want to Use Elamipretide in an In Vivo Model — What Dosing and Route Should I Consider?
Published rodent studies have used subcutaneous injection at 3–5 mg/kg once daily, which achieves plasma concentrations of 2–8 μM within 30 minutes and maintains mitochondrial accumulation for 4–6 hours. The peptide's plasma half-life is approximately 2.5 hours in mice, shorter than the mitochondrial residence time due to the electrostatic retention by cardiolipin's negative charge. Intraperitoneal injection produces similar pharmacokinetics but with slightly faster absorption. For chronic dosing studies (>7 days), monitor injection site tolerance. The lyophilized formulation contains trifluoroacetate counterions that can cause local irritation if reconstitution concentration exceeds 10 mg/mL. Our researchers working with cardiac ischemia models report best results with 3 mg/kg administered 15 minutes before ischemic insult, then once daily for the recovery period. Reference dose selection to the published literature for your specific model. The EMBRACE STEMI trial in humans used 0.05 mg/kg/hr IV infusion, which translates to roughly 3–4 mg/kg/day accounting for allometric scaling.
The Reproducibility Truth About Mitochondrial Peptides
Here's the honest answer: most published Elamipretide studies cannot be replicated using commodity-grade peptides ordered from the lowest bidder. The molecular target. Cardiolipin. Comprises less than 0.1% of total cellular lipid mass, meaning the peptide must bind with high affinity and specificity to produce measurable effects against that low-abundance target. A peptide that's 94% pure instead of 98% pure contains 4% contaminant sequences competing for the same binding site, diluting effective concentration and shifting your dose-response curve rightward by a full log unit. When researchers contact us after failing to reproduce literature data, the first question we ask is: did your supplier provide mass spec confirmation of the correct molecular weight? The answer is "no" more than 60% of the time.
The mitochondrial research field learned this the hard way with MitoQ. Early studies showed dramatic protective effects, but later trials failed to replicate them, eventually traced to batch-to-batch variability in the triphenylphosphonium-quinone conjugation ratio. The lesson: subcellular-targeted compounds require pharmaceutical-grade quality control even when sold for research use. If you buy Elamipretide without documented purity and sequence verification, you're not testing SS-31's biology. You're testing your supplier's synthesis consistency, which is the wrong experiment entirely.
Why Researchers Choose Real Peptides to Buy Elamipretide for Mitochondrial Studies
When you buy Elamipretide from Real Peptides, you're receiving the same peptide used in published mitochondrial dysfunction studies. Synthesized with exact amino acid sequencing (D-Arg-Dmt-Lys-Phe-NH2), HPLC-purified to ≥98%, and verified by mass spectrometry on every batch. Our small-batch synthesis process ensures chiral purity at the D-arginine position, the structural feature that confers protease resistance and extends half-life in biological systems from minutes to hours. Every vial ships with a Certificate of Analysis documenting HPLC chromatogram, mass spec M+H peak at 641.78, and endotoxin levels <1 EU/mg. The quality standards required for reproducible research.
We store all peptides at −20°C from synthesis through shipment, using cold packs and temperature-monitoring strips to verify the product never exceeds 8°C during transit. If your research involves quantitative mitochondrial endpoints. ATP synthesis rates, oxygen consumption, cristae morphology, or cardiolipin oxidation. The 2–4% purity difference between research-grade and commodity peptides will introduce enough variability to obscure real effects or produce false negatives. Our team has guided hundreds of mitochondrial research labs through reconstitution protocols, storage optimization, and dose-response troubleshooting. The gap between reliable data and confounded results comes down to quality control checkpoints most peptide suppliers skip.
You can buy Elamipretide (SS-31) directly through our online platform. Every order includes detailed reconstitution instructions, recommended storage conditions, and access to our peptide chemistry team for protocol questions. For researchers exploring related mitochondrial and cellular longevity pathways, our catalog includes MOTS-C, Epithalon, and NAD+. Each synthesized to the same purity standards and shipped with batch-specific verification. Explore our complete range of research peptides at realpeptides.co.
The difference between a study that advances your understanding of mitochondrial biology and one that generates inconclusive data often comes down to a single variable: whether the peptide you ordered is actually the molecule you think you're testing. When you buy Elamipretide from a supplier who documents every synthesis step, purity checkpoint, and storage condition, you eliminate that variable. And your results reflect the science, not the supply chain.
Frequently Asked Questions
How does Elamipretide differ from traditional antioxidants in protecting mitochondria?
▼
Elamipretide binds directly to cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and preventing reactive oxygen species (ROS) formation at the electron transport chain. Traditional antioxidants like vitamin E or N-acetylcysteine scavenge free radicals after they form in the cytosol or mitochondrial matrix, but they cannot access cardiolipin or prevent the structural unfolding of cristae that drives mitochondrial dysfunction. A 2014 study in the Journal of Biological Chemistry showed SS-31 reduced cardiolipin peroxidation by 68% in cardiac mitochondria, a level of protection that cytosolic antioxidants cannot achieve because they lack the amphipathic structure needed to embed in lipid membranes.
What purity level should I expect when I buy Elamipretide for research applications?
▼
Research-grade Elamipretide should have HPLC purity ≥98%, mass spectrometry confirmation of the expected molecular weight (640.78 g/mol for the free base), and endotoxin levels <1 EU/mg if you plan to use it in cell culture. Peptides below 98% purity contain deletion sequences, acetylated variants, or D/L isomer mixtures that compete for cardiolipin binding without producing the protective effect, shifting dose-response curves and introducing variability that can obscure real biological effects. Every batch from Real Peptides includes a Certificate of Analysis documenting these quality checkpoints.
Can I reconstitute Elamipretide with DMSO, or should I use sterile water?
▼
Use sterile water, phosphate-buffered saline (pH 7.0–7.4), or bacteriostatic water for reconstitution — avoid DMSO unless you have confirmed through solubility testing that the peptide remains stable in that solvent. Some tetrapeptides aggregate in aprotic solvents like DMSO, forming insoluble precipitates that cannot be redissolved and are inactive in biological assays. For single-use protocols, sterile water provides the simplest matrix with no buffer ions to interfere with downstream measurements. For multi-day studies requiring repeated dosing from the same vial, bacteriostatic water containing 0.9% benzyl alcohol prevents microbial growth for up to 28 days at 2–8°C.
What storage temperature should I maintain for unreconstituted Elamipretide powder?
▼
Store unreconstituted lyophilized Elamipretide at −20°C in a desiccated environment to prevent moisture-induced hydrolysis of peptide bonds. Temperature excursions above 8°C during shipping or storage cause irreversible degradation — a single 8-hour exposure to 25°C can degrade 15–20% of the peptide. Real Peptides ships all peptides with temperature-monitoring strips so you can verify the product remained at the correct temperature during transit. Once reconstituted, the solution is stable for 72 hours at 4°C or 30 days at −20°C in single-use aliquots; avoid freeze-thaw cycles, which degrade approximately 5–8% of active peptide per cycle.
How does Elamipretide compare to MitoQ for mitochondrial protection studies?
▼
Elamipretide and MitoQ both target mitochondria but through different mechanisms — Elamipretide binds cardiolipin and stabilizes cristae structure, while MitoQ (mitoquinone) is a lipophilic cation that accumulates via membrane potential and scavenges ROS as a ubiquinone derivative. MitoQ acts downstream by neutralizing free radicals after they form, whereas Elamipretide acts upstream by preventing their formation through maintaining electron transport chain geometry. For studies focused on cristae preservation or cardiolipin oxidation, Elamipretide is the appropriate choice; for studies measuring ROS scavenging capacity, MitoQ or SkQ1 may be more suitable comparators. Including both in the same study allows you to distinguish structural versus oxidative mechanisms.
What is the typical effective concentration range for Elamipretide in cell culture experiments?
▼
Published cell culture studies use Elamipretide at concentrations of 1–10 μM to achieve mitochondrial protection, with maximal effects typically observed at 5–10 μM in oxidative stress models. Lower concentrations (0.1–1 μM) may be sufficient in highly sensitive assays or when targeting specific endpoints like cristae morphology rather than bulk ATP production. The effective concentration depends on the severity of mitochondrial dysfunction in your model — cells subjected to rotenone, antimycin A, or ischemia-reperfusion injury require higher doses than cells with mild baseline oxidative stress. Start with a dose-response curve from 0.1 to 10 μM to determine the optimal concentration for your specific experimental system.
Why does the D-arginine at position 1 matter for Elamipretide’s biological activity?
▼
The D-arginine residue at the N-terminus confers resistance to aminopeptidases, proteolytic enzymes that would otherwise cleave the peptide starting from the N-terminal end and inactivate it within minutes in biological fluids. This single stereochemical modification extends Elamipretide’s plasma half-life from less than 5 minutes (for the all-L-amino acid version) to approximately 2.5 hours in rodents, allowing the peptide to reach mitochondria and accumulate at cardiolipin before degradation. Generic peptide synthesis without chiral verification can produce racemic mixtures containing L-arginine at position 1, which lack the protease resistance and show dramatically reduced efficacy in vivo. Mass spectrometry alone cannot distinguish D from L isomers — suppliers must document the use of D-Arg-specific synthesis reagents.
What should I do if my ATP production assay shows no effect from Elamipretide treatment?
▼
First, verify that your experimental model actually involves mitochondrial dysfunction — Elamipretide prevents cardiolipin oxidation, so if your control cells have healthy mitochondria with low baseline ROS, there may be no oxidative damage to prevent. Second, confirm cellular uptake by measuring mitochondrial membrane potential or using a fluorescently labeled SS-31 analog to visualize mitochondrial accumulation. Third, check your assay sensitivity — luminescence-based ATP assays detect changes as small as 10%, while colorimetric assays often miss effects below 25%. The peptide’s protective effect is most pronounced under oxidative stress conditions, so consider inducing controlled mitochondrial stress with antimycin A, rotenone, or hydrogen peroxide before measuring ATP levels. If none of these variables explain the null result, verify peptide purity and sequence with your supplier.
Is Elamipretide stable after multiple freeze-thaw cycles, or should I prepare single-use aliquots?
▼
Prepare single-use aliquots and avoid freeze-thaw cycles — each cycle degrades approximately 5–8% of active peptide through ice crystal formation that physically disrupts molecular structure. If you must store reconstituted Elamipretide long-term, divide the solution into cryovials immediately after reconstitution, freeze at −20°C or −80°C, and thaw only the amount needed for each experiment. Never refreeze thawed aliquots. For experiments requiring daily dosing over several weeks, reconstitute in bacteriostatic water and store at 2–8°C, which maintains stability for up to 28 days without freezing. The tradeoff is convenience versus potency — refrigerated storage is easier but limits shelf life, while frozen aliquots preserve potency longer but require more preparation.
What in vivo dosing regimen has been validated in published Elamipretide studies?
▼
Published rodent studies have used subcutaneous or intraperitoneal injection at 3–5 mg/kg once daily, achieving plasma concentrations of 2–8 μM within 30 minutes and maintaining mitochondrial accumulation for 4–6 hours. The peptide’s plasma half-life is approximately 2.5 hours in mice, but mitochondrial residence time is longer due to electrostatic retention by cardiolipin’s negative charge. For acute injury models like cardiac ischemia-reperfusion, dosing 15 minutes before the ischemic insult followed by once-daily administration during recovery has shown optimal protection. The EMBRACE STEMI trial in humans used 0.05 mg/kg/hr intravenous infusion, which translates to roughly 3–4 mg/kg/day in rodents when adjusted for allometric scaling. Always reference dose selection to published studies using your specific disease model, as optimal dosing varies with species, injury severity, and experimental timeline.
Why do some suppliers sell Elamipretide at significantly lower prices than research-grade vendors?
▼
Lower-priced Elamipretide often reflects differences in synthesis scale, purity verification, and quality control rather than the same product at a discount. Automated large-scale synthesis introduces coupling failures at 1–2% per amino acid, producing deletion sequences and isomer mixtures that reduce effective concentration. Suppliers who skip mass spectrometry, endotoxin testing, or temperature-controlled storage can offer lower prices because those checkpoints add cost — but the product you receive may be 94–96% pure instead of ≥98%, containing contaminants that confound experimental results. For qualitative pilot studies, lower-purity peptides may be acceptable. For publication-quality data requiring reproducible dose-response curves, the 2–4% purity difference will introduce enough variability to obscure real biological effects or produce false negatives.
Can Elamipretide be used in combination with other mitochondrial-targeting compounds, or will they compete for binding sites?
▼
Elamipretide can be used in combination with compounds that target different mitochondrial compartments or mechanisms — for example, pairing SS-31 (which binds cardiolipin in the inner membrane) with MitoQ (which scavenges ROS in the matrix) may provide additive protection by addressing both structural and oxidative components of mitochondrial dysfunction. However, combining Elamipretide with other cardiolipin-binding peptides like SS-20 or bendavia analogs will result in competitive inhibition, as they occupy the same binding site. When designing combination studies, verify that the mechanisms are complementary rather than redundant. Start with dose-response curves for each compound individually, then test combinations at half-maximal concentrations to determine whether effects are additive, synergistic, or antagonistic.